We can Assist any Publicly Traded Company Gain Greater Exposure Creating Increased Awareness and Liquidity in the Market Place (Retail or Private)
** Contact us for Custom Tailored Plans for Your situation
OxySure Therapeutics Inc. (OTCQB: OTCPK:OXYS) has grown its revenue for an impressive 15 consecutive quarters. While several analysts have taken note, setting price targets ranging from $1.90 to $2.30 per share, the stock has traded largely under-the-radar at just $0.17 per share.
The company trades at just 1.8x trailing 12-month revenue and 2.7x book value. By comparison, Cardica, Inc. (NASDAQ: CRDC), a larger company but one that has similar revenues in the medical equipment manufacturer space, trades at 82.5x trailing 12-month revenue and 10.5x book value.
In this article, we'll take a look at some of the company's recent progress and where it may be headed over the coming years.
Paving the Way
OxySure - doubled its production capacity in early February in order to address its rapidly increasing backlog of orders. During the third quarter of 2015, the company's net receivables jumped to $1,234,000 from $1,159,000 during the second quarter and $878,000 during the first quarter. These net receivables have been growing at a 10.3% compounded growth rate over the past four quarters and appear positioned to continue growing ahead.
"Through recent investments in infrastructure and additional manufacturing staff, we were able to reduce our current backlog from two months to one month," said OxySure Production Manager Richard Bryant in a February 10th press release. "We plan to further add additional production capacity by adding some anticipating process changes, as well as further acquisitions of equipment and additional manufacturing staff."
These investments have been supported through the City of Frisco's Economic Development Corporation and Sinacola Commercial - its landlord. This year, the company received the fifth of five incentives from the city designed to boost capital investment and job growth. These incentives helped management build up a multi-million dollar company, that employs a growing number of people in the emergency medical industry.
Focus on Profits
OxySure's revenues jumped nearly 40% during the third quarter of 2015, putting it on track for a $5 million run-rate moving into the new year. According to Julian T. Ross, Chairman and CEO, this run rate will accelerate to $10 million in 2016 and facilitate a breakeven on a cash flow basis.
On the product level, the company's growing client base is having a positive effect on its revenue mix. One-time unit sales may provide a nice boost to total revenue, but recurring revenue from the sale of replacement cartridges provider higher margins. In addition, the company's efforts to cross-sell products manufactured by other companies could have a similar impact on margins and bolster overall profitability over the long-term.
In early February, the company signed a supply agreement with ORS Nasco to offer complementary products to its institutional customers seeking a single source for their medical emergency preparedness. These products include first aid supplies, respiratory products, heat stress protection, eye protection, and many other product lines. Through this agreement, there are ample opportunities for revenue and margin expansion.
OxySure has made significant progress in building up its revenue over the past several years, but recent developments could accelerate this growth over the coming quarters. Investors in small-cap biotech stocks, like Allied Healthcare Products Inc. (NASDAQ: AHPI) and Akers Bioscience Inc. (NASDAQ: AKER), may want to take a look at the company given these recent developments.
OxySure Therapeutics, Inc.
The Complete Therapeutic Emergency Medical Device and Services Company
The future and upcoming year should be very exciting with OxySure anticipated to eclipse & smash previous sales and revenue records. This will be OXYSure's biggest year to date, with a projected $10,000,000 Million in sales/revenue minimum!!
We believe it is a good entry level, a most advantageous price for new investors and a great average out down position. A Diamond in the Rough LONG PLAY, with Short Term Gain potential.
Oxysure has now evolved into a complete Therapeutic Solutions company, offering a wide array of products for everyday emergency, and crisis intervention.
Robert E. Kreh
Small Cap Solutions, LLC
Disclaimer: You are receiving this message because you have recently requested it and/or in the past expressed an interest in or about information and updates concerning the company OxySure, Therapeutics, Inc., and/or other Micro/Small Cap Companies. This profile has been compiled by Small Cap Solutions, LLC based on information believed to be true. This profile is not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission - yahoofinance.com or otcmarkets.com Small Cap Solutions, LLC has received 39,179 Shares of Rule 144 Restricted Commom Stock from Oxysure Therapeutics, Inc. for investor relations services rendered. Additional inquiries available by email to firstname.lastname@example.org or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.
Disclaimer: All Micro/Small Cap Company(ies) profile(s) are/have been compiled by Small Cap Solutions, LLC based on information believed to be true and gathered either from client companies and/or third party('s)/web sites. These profiles are not guaranteed, neither implied, nor in writing, as to the accuracy and completeness of content, and has been prepared for information purposes only. As such, this profile may contain forward reaching statements, as defined in the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from the statements either expressed or implied herein. Prospective investors are advised to review the Company's periodic filings with the Securities and Exchange Commission or at yahoofinance.com or otcmarkets.com Small Cap Solutions, LLC may receive cash or stock from client companies for investor relations services rendered. Small Cap Solutions, LLC and/or its Principal/Employees are not registered Broker(s)/Broker Dealer(s) with FINRA or the SEC. Small Cap Solutions, LLC does not make any buy/sell recommendations at any time, but may state their opinion on companies, etc. That is not meant to be a recommendation. All information disseminated by Small Cap Solutions, LLC is believed to be true and public. Additional inquiries available by email to email@example.com or by mail to 303 Joppa Crossing Ct. (Suite#1) Joppa, Md. 21085. To unsubscribe to this mailing list, please reply "unsubscribe" to this message.
Small Cap Solutions, LLC may provide hyperlinks to third party websites or access to third party content. We do not control, endorse or guarantee content found in such sites. By accessing, viewing or using the website or communications originating from the website, you agree that Emerging Growth Corp, operators, owners and employees, are not responsible for any content, associated links, resources or services associated with a third party website.
SOURCE: Emerging Growth LLC
ReleaseID: 437147 Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org
Disclosure: I am/we are long "OXYS".